# Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®

> **NCT00355654** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 847 (actual)

## Conditions studied

- Infant
- Healthy

## Interventions

- **BIOLOGICAL:** DT5aP-IPV-Hib 5-component Pertussis vaccine
- **BIOLOGICAL:** DT3aP-HBs-IPV

## Key facts

- **NCT ID:** NCT00355654
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2007-09
- **Final completion:** 2008-07
- **Target enrollment:** 847 (ACTUAL)
- **Last updated:** 2015-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00355654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00355654, "Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00355654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*